A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

BMC Cancer

Volumn 11, Issue , 2011, Pages

  McKeage, Mark J ^a   Gu, Yongchuan ^a   Wilson, William R ^a   Hill, Andrew ^a   Amies, Karen ^a   Melink, Teresa J ^b   Jameson, Michael B ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Proacta Inc   (United States)

^c WAIKATO HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; PR 104; PR 104A; PRODRUG; UNCLASSIFIED DRUG; CHLORMETHINE DERIVATIVE; PR-104; PR-104A;

ADULT; AGED; ANEMIA; ANUS CANCER; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE SEVERITY; DOSE LIMITING TOXICITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG RESPONSE; DRUG TOXICITY; FEMALE; GLIOBLASTOMA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; SALIVARY GLAND TUMOR; SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; CLINICAL TRIAL; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; TREATMENT OUTCOME;

EID: 80053598625     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-432     Document Type: Article

References (24)

1. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 2007, 13(13):3922-3932. 10.1158/1078-0432.CCR-07-0478, 17606726.
2. Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR. DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity. Cancer Res 2009, 69(9):3884-3891. 10.1158/0008-5472.CAN-08-4023, 19366798.
3. Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, et al. The Bioreductive Prodrug PR-104A is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3. Cancer Res 2010, 70(4):1573-1584. 10.1158/0008-5472.CAN-09-3237, 20145130.
4. Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, Patterson AV. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: A role for NADPH: cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 2007, 74(6):810-820. 10.1016/j.bcp.2007.06.014, 17645874.
5. Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM, Thompson LH, Wilson WR. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther 2009, 8(6):1714-1723. 10.1158/1535-7163.MCT-08-1209, 19509245.
6. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998, 58(7):1408-1416.
7. Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, Chiu RK, Lambin P. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002, 38(2):240-257. 10.1016/S0959-8049(01)00361-6, 11803141.
8. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4(6):437-447. 10.1038/nrc1367, 15170446.
9. Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira JI, Okamura K, Yaegashi N, Sasano H. 17 beta-hydroxy steroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol 2006, 248(1-2):136-140. 10.1016/j.mce.2005.11.038, 16406263.
10. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T, et al. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008, 61(4):448-454. 10.1136/jcp.2007.050906, 17720776.
11. Sakurai M, Oishi K, Watanabe K. Localization of cyclooxygenases-1 and-2, and prostaglandin F synthase in human kidney and renal cell carcinoma. Biochem Biophys Res Commun 2005, 338(1):82-86. 10.1016/j.bbrc.2005.08.194, 16157291.
12. Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: Comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys 2007, 69(2):560-571. 10.1016/j.ijrobp.2007.05.049, 17869669.
13. Patel K, Choy SSF, Hicks KO, Melink TJ, Holford NH, Wilson WR. A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Cancer Chemother Pharmacol 2011, 67(5):1145-1155. 10.1007/s00280-010-1412-z, 20683596.
14. Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 2010, 65(4):791-801. 10.1007/s00280-009-1188-1, 20012293.
15. Gu Y, Atwell GJ, Wilson WR. Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans. Drug Metab Dispos 2010, 38(3):498-508. 10.1124/dmd.109.030973, 20019245.
16. Gu Y, Tingle MD, Wilson WR. Glucuronidation of Anticancer Prodrug PR-104A: Species Differences, Identification of Human UDP-Glucuronosyltransferases, and Implications for Therapy. J Pharmacol Exp Ther 2011, 337(3):692-702. 10.1124/jpet.111.180703, 21427202.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid Tumors. J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205, 10655437.
18. Gu Y, Wilson WR. Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(27):3181-3186. 10.1016/j.jchromb.2009.08.009, 19709934.
19. Atwell GJ, Denny WA. Synthesis of H-3- and H-2(4)-labelled versions of the hypoxia-activated pre-prodrug 2-((2-bromoethyl)-2,4-dinitro-6-(((2-(phosphonooxy)ethyl)amino)carbonyl) anilino)ethyl methanesulfonate (PR-104). J Label Compd Radiopharm 2007, 50(1-2):7-12.
20. Gu Y, Guise CP, Patel K, Abbattista MR, Lie J, Sun X, Atwell GJ, Boyd M, Patterson AV, Wilson WR. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice. Cancer Chemother Pharmacol 2011, 67(3):543-555. 10.1007/s00280-010-1354-5, 20473609.
21. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, Miners JO. S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 2005, 60(4):423-433. 10.1111/j.1365-2125.2005.02446.x, 1884820, 16187975.
22. Birtwistle J, Hayden RE, Khanim FL, Green RM, Pearce C, Davies NJ, Wake N, Schrewe H, Ride JP, Chipman JK, et al. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat Res 2009, 662(1-2):67-74.
23. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007, 104(13):5431-5436. 10.1073/pnas.0701152104, 1838452, 17374716.
24. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, et al. Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. PLoS One 2011, 6(8):e23108. 10.1371/journal.pone.0023108, 3154919, 21853076.